An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir; Drug: insulin aspart

Study type: Observational

Funder types: Industry

Identifiers

NCT01487421

ANA-1934

Details and patient eligibility

About

This study is conducted in Europe. The aim of this study is investigate the potential of a supplementary insulin therapy regimen (SIT) as intensification for insufficiently controlled patients with type 2 diabetes in a normal diabetes care setting.

Enrollment: 2,134 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Type 2 diabetes
• OAD monotherapy
• OAD combination therapy
• Therapy with OAD and basal insulin
• Conventional insulin therapy with premixed insulin

Trial design

2,134 participants in 1 patient group

SIT

Treatment:

Drug: insulin aspart

Drug: insulin detemir